Collaboration with Therapeutically-Focused CRO Responds to Customer Demand for InForm™ ITM Solutions

WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced an agreement with therapeutically-focused global contract research organization (CRO) INC Research to extend the benefits of its InForm™ Integrated Trial Management (ITM) solution to INC Research’s customers.

INC Research, headquartered in Raleigh, North Carolina, has 24 office locations worldwide. Its experienced, regionally-based professionals provide clinical services, data services, late phase services and therapeutic expertise in the specialty areas of the central nervous system, oncology and infectious disease, and in innovative pediatric and women’s health trials. INC Research has developed a proprietary Trusted Process® that is designed to deliver to its customers predictable, dependable outcomes and actionable results based on a proven, metrics-driven methodology.

“The agreement with Phase Forward is further proof of INC’s steadfast commitment to provide solutions that best meet each customer’s unique program requirements,” said Alistair Macdonald, executive vice president of global services, INC Research. “We have seen increasing demand from our customers for the use of InForm in their trials. The scale and complexity of many of our customers’ trials demand the robust technology offered in the InForm ITM solution, making it an excellent electronic data capture (EDC) option within our suite of data services. To date, INC Research has experience with over 100 EDC studies, and we are delighted to be working with Phase Forward as we enhance our breadth and depth of expertise.”

“As clinical trials continue to grow in number, increase in sophistication and expand in reach, many companies are turning to CROs,” said Mike Davies, vice president, global CRO partnerships at Phase Forward. “The expertise and experience of a CRO like INC Research provide a valuable advantage in helping customers maximize the benefits of electronic data capture offered in InForm.”

Phase Forward’s CRO partnership strategy is designed to assist CRO clients in achieving success in both the short and long term. Its customized structure and flexible pricing options help CROs of all sizes to invest in their own capabilities and capitalize on new growth opportunities. As of the end of 2008, Phase Forward had over 90 CRO customers across all of its solutions.

About INC Research Inc.

INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina, with 24 offices and operational in 36 countries. For more information please visit www.incresearch.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm™), phase I clinic automation (LabPas™), clinical data management (Clintrial™), clinical trials signal detection (CTSD™), strategic pharmacovigilance (Empirica Signal™) and Signal Management, adverse event reporting (Empirica Trace™), applied data standards (WebSDM™), Web-integrated interactive response technologies (Clarix™), and clinical data analysis and reporting automation and compliance (Waban SCE/CDR, Waban SMS and Waban LIMS). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, demand for Phase Forward’s products and services, future business and operations plans of a Phase Forward customer, and the ability of this Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, the possibility that customers’ needs or plans may change over time, and the possibility that the level of demand for Phase Forward’s products and services may vary. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.